| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Exploratory Research Department, Sanofi-Synthelabo Recherche, Toulouse, France
2 Exploratory Research Department, Sanofi-Synthelabo Recherche, Strasbourg, France
* To whom correspondence should be addressed. E-mail: claudine.serradeil{at}sanofi-synthelabo.com.
Vasopressin (AVP) receptors present in In-R1-G9 cells, a hamster glucagon-secreting 
-pancreatic cell line, were characterized using SSR149415, a selective nonpeptide V1b receptor antagonist and reference AVP compounds. Binding experiments, using [3H]-AVP as a ligand, identified a single population of high affinity binding sites. SSR149415 inhibited competitively this binding and exhibited nanomolar and stereospecific affinity for these sites. The affinity of various AVP/OT ligands confirmed a V1b binding profile. In functional studies, AVP was a potent stimulant in inducing intracellular Ca2+ increase, glucagon secretion and cell proliferation. These effects were fully antagonized by SSR149415 with a nanomolar potency whereas its diasteroisomer as well as two selective V1a and V2 receptor antagonists were much less potent. Additionally, the order of potency of AVP agonists and antagonists was in agreement with V1b-mediated effects. By RT-PCR, we confirmed the presence of V1b receptor mRNA in both In-R1-G9 cells and in human pancreas. The distribution pattern of V1b receptors investigated in human pancreas by immunohistochemistry showed strong labelling in islets of Langerhans and colocalization studies indicated that this receptor was expressed in -glucagon, 
-insulin and somatostatin pancreatic cells. Thus, in In-R1-G9 cells AVP mediates intracellular Ca2+ increase, glucagon secretion and cell proliferation by activating V1b receptors and these effects are potently antagonized by SSR149415. Moreover, the presence of V1b receptors also found in human Langerhans islets could suggest hormonal control of AVP in human pancreas.
This article has been cited by other articles:
|
|
 |
|
  A.-M. O'Carroll, G. M Howell, E. M Roberts, and S. J Lolait Vasopressin potentiates corticotropin-releasing hormone-induced insulin release from mouse pancreatic {beta}-cells J. Endocrinol., May 1, 2008; 197(2): 231 - 239. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Fujiwara, M. Hiroyama, A. Sanbe, T. Aoyagi, J.-i. Birumachi, J. Yamauchi, G. Tsujimoto, and A. Tanoue Insulin hypersensitivity in mice lacking the V1b vasopressin receptor J. Physiol., October 1, 2007; 584(1): 235 - 244. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. S.-L. Gal, D. Raufaste, S. Derick, J. Blankenstein, J. Allen, B. Pouzet, M. Pascal, J. Wagnon, and M. A. Ventura Biological characterization of rodent and human vasopressin V1b receptors using SSR-149415, a nonpeptide V1b receptor ligand Am J Physiol Regulatory Integrative Comp Physiol, August 1, 2007; 293(2): R938 - R949. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Shi, N. Cui, Y. Shi, X. Zhang, Y. Yang, and C. Jiang Arginine vasopressin inhibits Kir6.1/SUR2B channel and constricts the mesenteric artery via V1a receptor and protein kinase C Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2007; 293(1): R191 - R199. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Fujiwara, M. Hiroyama, A. Sanbe, J. Yamauchi, G. Tsujimoto, and A. Tanoue Mutual regulation of vasopressin- and oxytocin-induced glucagon secretion in V1b vasopressin receptor knockout mice J. Endocrinol., February 1, 2007; 192(2): 361 - 369. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Visit Other APS Journals Online |
